<DOC>
	<DOCNO>NCT02150967</DOCNO>
	<brief_summary>This multi-center , open label , single arm phase II study evaluate BGJ398 anti-tumor activity advance metastatic cholangiocarcinoma patient FGFR genetic alteration .</brief_summary>
	<brief_title>A Phase II , Single Arm Study BGJ398 Patients With Advanced Cholangiocarcinoma</brief_title>
	<detailed_description>Adult patient histologically cytologically confirm advanced metastatic cholangiocarcinoma FGFR2 gene fusion/ translocation FGFR genetic alteration evidence radiologic progression follow cisplatin-and gemcitabine-containing regimen advance disease gemcitabine-containing regimen consider intolerant cisplatin enrol . Approximately 55 adult patient age 18 , male female enrol . Of 55 patient , 40 patient cholangiocarcinoma identify FGFR2 gene fusion 15 patient may FGFR genetic alteration . All patient receive oral BGJ398 , daily , three week ( 21 day ) , one week ( 7 day ) schedule . One treatment cycle consist 28 day .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<criteria>Inlcusion criterion : Adult patient histologically cytologically confirm cholangiocarcinoma time diagnosis . Patients cancer gallbladder ampulla Vater eligible . Patients must receive least one prior regimen contain gemcitabine without cisplatin advanced/ metastatic disease . Patient evidence progressive disease follow prior regimen , prior treatment discontinue due toxicity must continue evidence measurable evaluable disease . Exclusion criterion : Prior current treatment MEK selective FGFR inhibitor insufficient organ function ANC &lt; 1,000/mm3 [ 1.0 x 109/L ] Platelets &lt; 75,000/mm3 [ 75 x 109/L ] Hemoglobin &lt; 109.0 g/dL Total bilirubin &gt; 1.5x ULN AST/SGOT ALT/SGPT &gt; 2.5x ULN ( AST ALT &gt; 5x ULN presence liver metastasis ) Serum creatinine &gt; 1.5x ULN calculate measured creatinine clearance &lt; 45 mL/min Inorganic phosphorus outside normal limit Total ionize serum calcium outside normal limit Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>cholangiocarcinoma ,</keyword>
	<keyword>FGFR2 gene fusion ,</keyword>
	<keyword>FGFR genetic alteration</keyword>
</DOC>